Barclays lowered the firm’s price target on Encompass Health (EHC) to $140 from $153 and keeps an Overweight rating on the shares. The firm updated the company’s model post the Q1 report. High occupancy rates may constrain Encompass’ volume growth near-term, but there is evidence of further opportunity to meet demand with de novo development, the analyst tells investors in a research note.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on EHC:
- Encompass Health Lifts 2026 Outlook After Strong Q1
- Encompass Health price target lowered to $150 from $160 at BofA
- Encompass Health (EHC) Q1 Earnings Cheat Sheet
- Encompass Health: Maintaining a Buy on Intact Long‑Term Earnings Power Despite Near‑Term Volume Noise
- Encompass Health: Medicare Rate Proposal Reinforces Pricing Outlook and Supports Buy Rating